RANDOMIZED STUDY OF PHASE I / II OF TRASTUZUMAB (HERCEPTIN) AND ZD1839 (IRESSA) IN PATIENTS WITH CANCER OF MASSASTASICO ON EXPRESSING HER 2 POSITIVE
Not Applicable
- Conditions
- -C50 Malignant neoplasm of breastMalignant neoplasm of breastC50
- Registration Number
- PER-075-03
- Lead Sponsor
- EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG),
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Men and women with metastatic cancer with diagnosis
histological confirmation of adenocarcinoma overexpressing HER2 / neu
who have had or not first line of standard chemotherapy
Age> 18 years
Women should not be pregnant or nursing. Have a negative pregnancy test within 14 days prior to registration, if pre or perimenopausal.
Exclusion Criteria
Minors
Pregnant
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method